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ABSTRACT 
The purpose of this study was to examine the expression profiles of a drug 
metabolizing enzyme cytochrome P450 (CYP) 3A62 mRNA in the intestine and liver 
of normal male Wistar rats, and its regional differences in the intestinal tract. 
Nine-week-old male rats were used, and their intestine were divided equally into nine 
segments. The expression patterns of CYP3A62 mRNA in the intestine and liver were 
examined using a reverse transcription-polymerase chain reaction (RT-PCR). The PCR 
products for CYP3A62 mRNA were readily detectable in the intestine of normal male 
rats, whereas no bands for CYP3A62 mRNA were detected in the liver using similar 
PCR conditions as those used in the intestine. The expression of CYP3A62 mRNA was 
found to be high in the jejunum, and stable until the bottom of the small intestine. Only 
the decreased expression pattern in the bottom of the intestine was contradictory to our 
previous findings on CYP3A9 and CYP3A18 mRNAs. Unlike other CYPs of the 
CYP3A subfamily, CYP3A62 was found to be predominant in the intestine rather than 
the liver of normal male Wistar rats. This suggests that CYP3A62 also has an important 
role in the detoxification of xenobiotics similar to endogenous substances as an 
absorptive barrier in the intestine. These findings may help the evaluation of 
gastrointestinal drug absorption and drug-drug interaction in rats. 
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INTRODUCTION 
 
The cytochrome P450-dependent 
microsomal monooxygenase system 
consists of a flavoprotein, cytochrome 
P450 reductase, and a multigene 
superfamily of hemeproteins (the 
cytochrome P450s - CYPs). CYPs 
belonging to the CYP3A subfamily are 
among the most abundant, being 
predominantly expressed in the liver, but 
are also present in the gut, leukocytes, and 
brain (Ding and Kaminsky 2003; Miksys 
and Tyndale 2002). In addition, the 
CYP3A subfamily may contribute to the 
metabolism of approximately 50% of 
marketed drugs (Wringhton and Ring 
1999). Thus, the CYP3A subfamily plays 
an important role in the detoxification of 
xenobiotics as well as endogenous 
substances. 
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In rats, five CYP3A cDNAs have been 
characterized; CYP3A1 (Gonzalez et al., 
1985), CYP3A2 (Gonzalez et al., 1986), 
CYP3A9 (Wang et al., 1996), CYP3A18 
(Nagata et al., 1996; Strotkamp et al., 
1995), and CYP3A23 (Kirita and 
Matsubara 1993; Komori and Oda 1994). 
CYP3A23 was, however, identified as 
having the same structure as CYP3A1 
(Nagata et al., 1999).   The existence of 
these in the intestine of rats has been 
demonstrated by various experimental 
techniques, whereas some have reported 
that the CYP3A subfamily is not 
expressed in this organ (Chiba et al., 
1997; de Waziers et al., 1990; Kolars et 
al., 1992; Watkins et al., 1987; Zhang et 
al., 1996). Therefore, we have examined 
the expression profiles of the CYP3A 
subfamily in the intestine of normal male 
Wistar rats, and previously clarified that 
CYP3A1 and CYP3A2 mRNAs are not 
detected in the intestine of rats, but 
CYP3A9 and CYP3A18 mRNAs are 
readily detectable using a reverse 
transcription-polymerase chain reaction 
(RT-PCR) (Takara et al., 2003). However, 
Matsubara et al (2004) demonstrated the 
expression of a novel CYP3A form, 
CYP3A62, in the intestine of 
Sprague-Dawley rats. 
 
In the present study, the expression 
profiles of CYP3A62 mRNA were 
examined in both the intestine and liver of 
normal male Wistar rats using RT-PCR. 
In addition, the present findings on 
CYP3A62 were compared with those of 
other CYP3A isoforms (Takara et al., 
2003). 
 
MATERIALS AND METHODS 
 
Animals 
Nine-week-old male Wistar rats (240 to 
250 g) were purchased from Japan SLC, 
Inc. (Hamamatsu, Japan). After an 
overnight fast with free access to water, 
rats were anesthetized by an 
intraperitoneal injection of pentobarbital 
sodium (Nembutal injection®, Dainippon 
Pharmaceutical Co., Ltd., Osaka, Japan), 
and sacrificed by exsanguination via the 
aorta in the abdomen. Animal 
experimental protocols were carried out in 
accordance with the Guidelines for 
Animal Experimentation at Kyoto 
Pharmaceutical University. 
 
Removal of Tissue and RNA Extraction 
The removal and the extraction of total 
RNA from rat tissue samples were carried 
out as previously reported (Takara et al., 
2003). That is, the intestine was excised 
quickly after exsanguination, and rinsed in 
ice-cold 0.9% NaCl solution. The 
intestine (total of ca. 90 cm) was divided 
into three parts; upper (almost 
corresponding to the duodenum, ~30 cm 
immediately distal to the pyloric valve), 
middle (almost corresponding to the 
jejunum, the 30 cm between the upper and 
lower sites), and lower (almost 
corresponding to the ileum, the last 30 cm 
before the cecum). Each part was further 
divided into three sections (about 10 cm 
each), and the centers (1 cm distal) were 
cut out to obtain nine segments. These 
were designated as S1, S2, S3, S4, S5, S6, 
S7, S8, and S9, in the direction of the 
duodenum to the ileum. The liver was 
excised quickly after exsanguination, and 
divided into parts (3 mm squares). Tissue 
samples of both the intestine and liver 
were collected from three rats, immersed 
quickly into RNAlaterTM (Sigma-Aldrich 
Chemical Co., St. Louis, MO), and stored 
at –80°C until RNA extraction. 
 
For RNA extraction, 3-mm squares of 
tissue samples were homogenized in 
RNAlaterTM using a pestle, then total 
RNA was extracted using a GenEluteTM 
Mammalian Total RNA kit 
(Sigma-Aldrich) as previously reported 
(Takara et al., 2003). 
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RT-PCR 
RT-PCR analysis was performed as 
described previously (Takara et al., 2003). 
Aliquots (0.3 µg) of total RNA were used 
for reverse transcription with an RNA 
PCR kit (AMV) ver. 2.1 (TakaraBio Inc., 
Shiga, Japan). The RT reaction was 
conducted in 15 µl RT reaction mixture, 
and this was incubated at 30°C for 10 min 
and subsequently at 42°C for 30 min in a 
thermal cycler (iCycler Thermal Cycler, 
Bio-Rad Laboratories, Inc., CA). The RT 
reaction was terminated by heating to 
99°C for 5 min, followed by cooling at 
5°C for 5 min in a thermal cycler 
(Bio-Rad). 
 
PCR primer sequences for amplification of 
CYP3A62 and glyceraldehyde-3-phos 
-phate dehydrogenase (GAPDH) are listed 
in Table 1 (Matsubara et al., 2004), and 
were synthesized by Proligo Japan K.K. 
(Kyoto, Japan). PCR amplification of 
cDNA was performed in a total reaction 
volume of 25 µl including 5 µl of RT 
product, using an RNA PCR kit (AMV) 
ver. 2.1 (TakaraBio). After initial 
denaturation at 95°C for 1 min, both 
CYP3A62 and GAPDH cDNAs were 
amplified for 22 cycles with 30 sec at 
94°C for denaturation, 1 min at 60°C for 
annealing and 1 min at 72°C for extension, 
followed by a final extension period of 10 
min at 72°C, using a thermal cycler 
(Bio-Rad). PCR products were separated 
on Tris-acetate-EDTA 3% agarose gels 
containing 100 ng/ml ethidium bromide, 
and photographed under ultraviolet 
illumination at 312 nm with a Polaroid 
camera. Band densities were measured 
using the computer program NIH Image 
version 1.63 (National Institutes of Health, 
Bethesda, MD), and band density ratio 
(CYP3A62/GAPDH) was calculated. 
 
Statistical Analysis 
Results are expressed as percentages of 
the ratio of CYP3A62 to GAPDH mRNA 
levels in the S1 region. These data were 
compared with the S1 region by 
non-repeated measures one-way analysis 
of variance followed by the Bonferroni 
test. The p values of less than 0.05 
(two-tailed) were considered significant. 
 
RESULTS AND DISCUSSION 
 
In this study, the intestinal expression 
profile of a drug metabolizing enzyme 
CYP3A62, isolated and characterized by 
Matsubara et al (2004), was examined in 
normal male Wistar rats using RT-PCR. 
In addition, the findings on CYP3A62 
were compared with those of other 
documented CYP3A isoforms (Takara et 
al., 2003). 
 
First, the expression of CYP3A62 mRNA 
was compared in the intestine and liver of 
Table 1: Gene-specific oligonucleotide primers used in PCR reaction for mRNA detection 
Gene  Sequence Fragment sizea)
CYP3A62 Forward Primer 
Reverse Primer 
5’-GGA AAT TCG ATG TGG AGT GC-3’ 
5’-AGG TTT GCC TTT CTC TTG CC-3’ 
544 
GAPDH Forward Primer 
Reverse Primer 
5’-CGA TCC CGC TAA CAT CAA AT-3’ 
5’-GGA TGC AGG GAT GAT GTT CT-3’ 
391 
a)Area amplified refers to sequences deposited at GenBank with accession numbers as follows: 
AB084894 for CYP3A62 (937–1481) and AF106860 for GAPDH (1083–1473). The primer 
sequences for GAPDH were designed by Primer3 software (Rozen and Skaletsky 2000). 
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normal male rats. The 544 bp PCR 
product for CYP3A62 mRNA was readily 
detectable in the intestine of normal male 
rats, whereas there was no band for 
CYP3A62 mRNA in the liver using the 
same PCR cycling conditions (Fig. 1). 
However, a faint band for CYP3A62 
mRNA was detected in the normal liver 
with an increase of the PCR cycle number 
(data not shown). These results indicate 
that the expression of CYP3A62 mRNA is 
predominant in the intestine rather than 
the liver. This was supported by results 
from normal male Sprague-Dawley rats, 
in which the expression level of 
CYP3A62 mRNA in the intestine was a 
few-fold higher than in the liver 
(Matsubara et al., 2004) 
 
Regional differences in CYP3A62 mRNA 
intestinal expression were also examined. 
The expression of CYP3A62 mRNA 
increased from the upper to the lower 
intestine in normal rats, and was 
significantly higher in the S4 and S8 than 
in the S1 region (Fig. 2). In addition, the 
expression level of CYP3A62 mRNA was 
similar from S4 to S9 regions (Fig. 2). 
Matsubara et al (2004) demonstrated that 
the expression level of CYP3A62 mRNA 
decreased slightly from the duodenum to 
the ileum. The discrepancy between our 
findings and theirs may be explained by 
differences in rat strain or the removal 
sites in the intestine. CYP3A62 mRNA 
was found to be expressed in both the 
intestine and liver, but predominantly in 
the intestine of normal male Wistar rats. 
Also, a regional difference in the intestine 
was noted in the expression of CYP3A62 
mRNA. 
  
Previously, we found that CYP3A9 and 
CYP3A18 mRNAs are readily detectable 
in the intestine, whereas CYP3A1 and 
CYP3A2 mRNAs were undetected by 
RT-PCR (Takara et al., 2003). In addition, 
both CYP3A9 and CYP3A18 mRNA 
levels were high in the duodenum, and 
decreased from the top to the bottom of 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Expression profiles for CYP3A62 mRNA in the intestinal tract and liver of male Wistar
rats as determined by RT-PCR. Rats were sacrificed, and their tissues were quickly collected
into RNAlaterTM. Total RNA was extracted from the tissue using a GenEluteTM Mammalian Total 
RNA kit. PCR products were separated on a 3% agarose gel containing 100 ng/ml ethidium
bromide, to visualize the DNA bands. M.W., Molecular weight marker (100 bp DNA ladder). 
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the gut, indicating the regional differences 
in both CYP3A9 and CYP3A18 mRNA 
expression. Taking previous reports into 
consideration, the expression profile of 
CYP3A62 mRNA in the intestine appears 
similar to those of CYP3A9 and 
CYP3A18 mRNAs, but not CYP3A1 and 
CYP3A2 mRNAs. However, the 
expression pattern of CYP3A62 mRNA 
specifically in the bottom of the intestine 
was different from those of CYP3A9 and 
CYP3A18 mRNAs (Takara et al., 2003). 
In contrast to these findings, it is generally 
accepted that the expression level of 
CYPs decreases from the top to the 
bottom of the gut (Kaminsky and Fasco 
1991). Consequently, the expression 
profiles of CYP3A62 mRNA may differ 
from those of others in the CYP3A 
subfamily in the intestine of normal male 
Wistar rats. 
 
In conclusion, CYP3A62 in normal male 
Wistar rats was found to be predominant 
in the intestine rather than in the liver, 
suggesting that it may have an important 
role in the detoxification of xenobiotics 
similar to endogenous substances as an 
absorptive barrier in the intestine. 
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Figure 2: Regional differences in CYP3A62 mRNA expression in the intestinal tract of normal
male Wistar rats as determined by RT-PCR. Rats were sacrificed, and their tissues quickly 
collected into RNAlaterTM. Total RNA was extracted from the tissue using a GenEluteTM
Mammalian Total RNA kit. PCR products were separated on a 3% agarose gel containing 100
ng/ml ethidium bromide, to visualize the DNA bands. (A) Representative electrophoretogram of
CYP3A62 and GAPDH. CYP3A62 and GAPDH were 544 bp and 391 bp long, respectively. (B) 
Data were obtained after densitometric analysis of electrophoretograms derived from three rats.
Results are expressed as percentages of the ratio of CYP3A62 to GAPDH mRNA levels in the
S1 region. Each bar represents the mean ± S.E. of three rats. * p<0.05 significantly different from 
S1. 
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